Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With CSL
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with long-time Australian partner could add up to $100 million to Merck's business in the 2010/2011 flu season, analyst says.
You may also be interested in...
Vaccine Market Will Wax And Wane Next Year: Universal Flu Shot Recommendation Comes As Firms Lose Pandemic Sales
A CDC advisory committee recommendation for universal seasonal influenza immunization in the U.S. could help cushion the loss of pandemic flu vaccine sales for drug companies during the 2010-2011 flu season
Vaccine Market Will Wax And Wane Next Year: Universal Flu Shot Recommendation Comes As Firms Lose Pandemic Sales
A CDC advisory committee recommendation for universal seasonal influenza immunization in the U.S. could help cushion the loss of pandemic flu vaccine sales for drug companies during the 2010-2011 flu season
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
J&J follows its brethren into vaccines, and Crucell lands a big-pharma partner in the wake of its failed deal with Wyeth.